Рецепт. 2019; : 695-702
Дорипенем в практике антибактериальной терапии пациентов с жизнеугрожающими инфекциями
Аннотация
Вопросы антибактериальной терапии жизнеугрожающих инфекций остаются серьезной проблемой современной медицины, несмотря на существенный прогресс в реаниматологии, хирургии и фармацевтической промышленности. Это, прежде всего, обусловлено возрастающей резистентностью возбудителей заболеваний как в стационарах, так и в амбулаторных условиях. Дорипенем – карбапенемный антибиотик, характеризующийся широким спектром антибактериальной активности в отношении полирезистентных грамположительных, грамотрицательных аэробных и анаэробных микроорганизмов. На настоящий момент была продемонстрирована его высокая клиническая эффективность, хорошая переносимость и безопасность в практике лечения тяжелых осложненных инфекций кожи и мягких тканей, интраабдоминальных инфекций, инфекций мочевыделительной системы, а также нозокомиальной, в том числе вентилятор-ассоциированной, пневмонии.
Список литературы
1. Vincent J.L., Bihari D.J., Suter P.M. (2015) The prevalence of nosocomial infection in intensive care units in Europe. Results of European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA, vol. 274, no 8, pp. 639–644.
2. Galkin D.V. (2007) Karbapenemy cherez 20 let posle otkrytiya: sovremennye mikrobiologicheskie i klinicheskie aspekty [Сarbapenems through 20 years after discovery: modern microbiological and clinical aspects]. Klin mikrobiol antimikrob himioter, vol. 9 (2), pp. 1335–52.
3. Gruss E., Tomas J.F., Bernis C., Rodriguez F. (1996) Nephroprotective effect of cilastatin in allogeneic bone marrow transplantation. Results from a retrospective analysis. Bone Marrow Transplant, vol. 18, pp. 761–5.
4. Norrby S.R. (1995) Carbapenems. Med Clin North Am., vol. 79, pp. 7G45–59.
5. Tsuji M., Ishii Y., Ohno A. (1998) In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother, vol. 42, pp. 94–9.
6. Zhanel G.G., Johanson C., Embil J.M. (2005) Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther., vol. 3, pp. 23–39.
7. Jones R.N., Huyth H.K., Biedenbach D.J. (2004) Activities of doripenem against drug-resistant clinical pathogens. Antimicrob Agents Chemother, vol. 48, pp. 3136–40.
8. Jones R.N., Sader H.S., Fritsche N.R. (2005) Comparative activity of doripenem and three other carbapenems tested against Cram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis., vol. 52, pp. 71–4.
9. Traczewski M.M., Brown S.D. (2006) In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother., vol. 50, pp. 819–21.
10. Chen Y., Garber E., Zhao Q. (2006) In vitro activity of doripenem against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother, vol. 49, pp. 2510–11.
11. Aranza-Torres M.K., Pillar C.M., Sahm D. (2007) Stratified analysis of doripenem activity against Enterobacteriaceae and Pseudomonas aeruginosa according to patient location: Inpatients and ICU patients. Program and Abstracts of 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
12. Zhanel G.G., Wiebe R., Dilay L., Thompson K., Rubinstein E., Hoban D.J. (2007) Comparative review of the carbapenems. Drugs, vol. 67 (7), pp. 1027–52.
13. Anderson D.L. (2006) Doripenem. Drugs Today, vol. 42, pp. 399–404.
14. Brown N.P., Jones M.E., Draghi D.C., Crites E. (2007) Profile of doripenem activity against gram-positive pathogens: results of a 2005–2006 surveillance initiative. Program and Abstracts of 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
15. Kim A., Banevicius M.F., Nicolau D.P. (2007) In vivo efficacy of doripenem human-simulated exposures against Pseudomonas aeruginosa. Program and Abstracts of 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
16. Bhavnani S.M., Hammel J.P., Cirincione B.B., Wikler M.A., Ambrose P.G. (2005) Use of pharmacokineticpharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother, vol. 49, pp. 3944–47.
17. Instrukciya po primeneniyu lekarstvennogo sredstva dorenem [The instruction for use of the drug dorenem]. Available at: https://www.rceth.by/NDfiles/instr/15_11_2419_i.
18. Nishino T., Otsuki M., Izawa M. (2007) In vitro and in vivo antibacterial activity of S-4661, a new carbapenem antibiotic. Abstr. F115. Program and Abstracts of 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
19. Kobayshi Y., Kizaki M., Mutou A. (1997) Synergy with S-4661 and vancomycin and teicoplanin against imipenem-resistant MRSA identified by the PCR method. Abstr. E216. Program and Abstracts of 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
20. Mushtaq S., Warner M., Ge Y., Kaniga K., Livermore D.M. (2005) In vitro interactions of doripenem with other antibacterial agents. Program and Abstracts of 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
21. Floren L.C., Wikler M.A., Kilfoil T., Ge Y. (2004) A phase I open-label controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of doripenem (DOR) administered intravenously withrenal impairment. Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology, Washington D.C.
22. Trye d., Kilfoil T., Leighton A., Wikler M. (2003) Doripenem: A phase I study to evaluate safety, tolerability and pharmacokinetics in western healthy volunteer population. Program and Abstracts of the 43th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
23. Floren L.C., Wikler M.A., Kilfoil T., Ge Y. (2004) A phase I double-blind, placebo-controlled study to determine the safety, tolerability and pharmacokinetics (PK) of prolonged-infusion regimens of doripenem (DOR) in healthy subjects. Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
24. Doribax. Raritain N.J. Ortho-Meneil Pharmaceutical Inc., 2007.
25. Nakajima Y., Mizobuchi M., Nakamura M. 92004) Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos., vol. 32, pp. 1383–91.
26. Kirsten Vannice, Eileen Benoliel, Kelly Kauber (2019) Clinical Klebsiella Pneumoniae Isolate With Three Carbapenem Resistance Genes Associated With Urology Procedures – King County, Washington, 2018 Morbidity and Mortality Weekly Report, vol. 68(30), pp. 667–668.
27. Kyle Rizzo, Sam Horwich-Scholefield, Erin Epson (2019) Carbapenem and Cephalosporin Resistance among Enterobacteriaceae in Healthcare-Associated Infections, California, USA. Emerging Infectious Diseases, vol. 25(7), pp. 1389–1393.
28. Walters M.S., Grass J.E., Bulens S.N. (2019) Carbapenem-Resistant Pseudomonas Aeruginosa at US Emerging Infections Program Sites, 2015. Emerging Infectious Diseases, vol. 25(7), pp. 1281–1288.
29. Lucasti C., Jasovich A., Umeh O., Jiang J., Kaniga K. (2007) Treatment of complicated intra-abdominal infections: doripenem versus meropenem. Int. J. Antimicrob Agents, vol. 29 (suppl 2), pp. S212.
30. Solomkin J., Umeh O., Jiang J. (2007) Doripenem versus meropenem with an option for oral step-down therapy in treatment of complicated intra-abdominal infections. Program and Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
31. Chastre J., Wunderink R., Prokocimer P., lee M., Kaniga K., Friedland I. (2008) Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumoniae; multicenter, randomized study. Crit Care med., vol. 36 (4), pp. 1089–96.
32. Anderson D.L. (2006) Doripenem. Drugs Today, vol. 42, pp. 399–404.
33. Psathas P.A., Kuzmission A., Ikeda K., Yasuo S. (2007) Stability of doripenem for injection (500 mg) in representative infusion fluids and containers. Program and Abstracts of 2007 American Society of Healthsystem Pharmacists summer Meeting; June 24–27, San Francisco, C.A.
34. (2007) Invans [package insert]. Whitehouse Station, NJ: Merk&Co.
35. Kays M.B., Fleming M.R., Cheatham S.C. (2014) Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Ann Pharmacother., vol. 48(2), pp. 178–186.
36. Roberts J.A., Lipman J. (2013) Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med., vol. 41(2), pp. 489–495.
37. Chung E.K., Fleming M.R., Cheatham S.C. (2017) Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients. Ann Pharmacother., vol. 51(3), pp. 209–218.
38. Alobaid A.S., Hites M., Lipman J. (2016) Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. Int. J. Antimicrob Agents., vol. 47(4), pp. 259–268.
Recipe. 2019; : 695-702
Doripenem in Antibacterial Therapy of Patients with Life-Threating Infections
Abstract
The issues of antibiotic therapy of life-threatening infections remain a serious problem of modern medicine, despite significant progress in resuscitation, surgery and pharmaceutical industry. This is primarily due to the increasing resistance of pathogens both in hospitals and on an outpatient basis. Doripenem is a carbapenemic antibiotic characterized by a wide spectrum of antibacterial activity against multiresistant gram-positive, gram-negative aerobic and anaerobic microorganisms. At present, it has demonstrated its high clinical efficacy, good tolerance and safety in treating severe complicated infections of the skin and soft tissues, intra-abdominal infections, urinary tract infections, nosocomial as well as ventilator-associated pneumonia.
References
1. Vincent J.L., Bihari D.J., Suter P.M. (2015) The prevalence of nosocomial infection in intensive care units in Europe. Results of European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA, vol. 274, no 8, pp. 639–644.
2. Galkin D.V. (2007) Karbapenemy cherez 20 let posle otkrytiya: sovremennye mikrobiologicheskie i klinicheskie aspekty [Sarbapenems through 20 years after discovery: modern microbiological and clinical aspects]. Klin mikrobiol antimikrob himioter, vol. 9 (2), pp. 1335–52.
3. Gruss E., Tomas J.F., Bernis C., Rodriguez F. (1996) Nephroprotective effect of cilastatin in allogeneic bone marrow transplantation. Results from a retrospective analysis. Bone Marrow Transplant, vol. 18, pp. 761–5.
4. Norrby S.R. (1995) Carbapenems. Med Clin North Am., vol. 79, pp. 7G45–59.
5. Tsuji M., Ishii Y., Ohno A. (1998) In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother, vol. 42, pp. 94–9.
6. Zhanel G.G., Johanson C., Embil J.M. (2005) Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther., vol. 3, pp. 23–39.
7. Jones R.N., Huyth H.K., Biedenbach D.J. (2004) Activities of doripenem against drug-resistant clinical pathogens. Antimicrob Agents Chemother, vol. 48, pp. 3136–40.
8. Jones R.N., Sader H.S., Fritsche N.R. (2005) Comparative activity of doripenem and three other carbapenems tested against Cram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis., vol. 52, pp. 71–4.
9. Traczewski M.M., Brown S.D. (2006) In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother., vol. 50, pp. 819–21.
10. Chen Y., Garber E., Zhao Q. (2006) In vitro activity of doripenem against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother, vol. 49, pp. 2510–11.
11. Aranza-Torres M.K., Pillar C.M., Sahm D. (2007) Stratified analysis of doripenem activity against Enterobacteriaceae and Pseudomonas aeruginosa according to patient location: Inpatients and ICU patients. Program and Abstracts of 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
12. Zhanel G.G., Wiebe R., Dilay L., Thompson K., Rubinstein E., Hoban D.J. (2007) Comparative review of the carbapenems. Drugs, vol. 67 (7), pp. 1027–52.
13. Anderson D.L. (2006) Doripenem. Drugs Today, vol. 42, pp. 399–404.
14. Brown N.P., Jones M.E., Draghi D.C., Crites E. (2007) Profile of doripenem activity against gram-positive pathogens: results of a 2005–2006 surveillance initiative. Program and Abstracts of 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
15. Kim A., Banevicius M.F., Nicolau D.P. (2007) In vivo efficacy of doripenem human-simulated exposures against Pseudomonas aeruginosa. Program and Abstracts of 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
16. Bhavnani S.M., Hammel J.P., Cirincione B.B., Wikler M.A., Ambrose P.G. (2005) Use of pharmacokineticpharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother, vol. 49, pp. 3944–47.
17. Instrukciya po primeneniyu lekarstvennogo sredstva dorenem [The instruction for use of the drug dorenem]. Available at: https://www.rceth.by/NDfiles/instr/15_11_2419_i.
18. Nishino T., Otsuki M., Izawa M. (2007) In vitro and in vivo antibacterial activity of S-4661, a new carbapenem antibiotic. Abstr. F115. Program and Abstracts of 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
19. Kobayshi Y., Kizaki M., Mutou A. (1997) Synergy with S-4661 and vancomycin and teicoplanin against imipenem-resistant MRSA identified by the PCR method. Abstr. E216. Program and Abstracts of 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
20. Mushtaq S., Warner M., Ge Y., Kaniga K., Livermore D.M. (2005) In vitro interactions of doripenem with other antibacterial agents. Program and Abstracts of 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
21. Floren L.C., Wikler M.A., Kilfoil T., Ge Y. (2004) A phase I open-label controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of doripenem (DOR) administered intravenously withrenal impairment. Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology, Washington D.C.
22. Trye d., Kilfoil T., Leighton A., Wikler M. (2003) Doripenem: A phase I study to evaluate safety, tolerability and pharmacokinetics in western healthy volunteer population. Program and Abstracts of the 43th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
23. Floren L.C., Wikler M.A., Kilfoil T., Ge Y. (2004) A phase I double-blind, placebo-controlled study to determine the safety, tolerability and pharmacokinetics (PK) of prolonged-infusion regimens of doripenem (DOR) in healthy subjects. Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
24. Doribax. Raritain N.J. Ortho-Meneil Pharmaceutical Inc., 2007.
25. Nakajima Y., Mizobuchi M., Nakamura M. 92004) Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos., vol. 32, pp. 1383–91.
26. Kirsten Vannice, Eileen Benoliel, Kelly Kauber (2019) Clinical Klebsiella Pneumoniae Isolate With Three Carbapenem Resistance Genes Associated With Urology Procedures – King County, Washington, 2018 Morbidity and Mortality Weekly Report, vol. 68(30), pp. 667–668.
27. Kyle Rizzo, Sam Horwich-Scholefield, Erin Epson (2019) Carbapenem and Cephalosporin Resistance among Enterobacteriaceae in Healthcare-Associated Infections, California, USA. Emerging Infectious Diseases, vol. 25(7), pp. 1389–1393.
28. Walters M.S., Grass J.E., Bulens S.N. (2019) Carbapenem-Resistant Pseudomonas Aeruginosa at US Emerging Infections Program Sites, 2015. Emerging Infectious Diseases, vol. 25(7), pp. 1281–1288.
29. Lucasti C., Jasovich A., Umeh O., Jiang J., Kaniga K. (2007) Treatment of complicated intra-abdominal infections: doripenem versus meropenem. Int. J. Antimicrob Agents, vol. 29 (suppl 2), pp. S212.
30. Solomkin J., Umeh O., Jiang J. (2007) Doripenem versus meropenem with an option for oral step-down therapy in treatment of complicated intra-abdominal infections. Program and Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C.
31. Chastre J., Wunderink R., Prokocimer P., lee M., Kaniga K., Friedland I. (2008) Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumoniae; multicenter, randomized study. Crit Care med., vol. 36 (4), pp. 1089–96.
32. Anderson D.L. (2006) Doripenem. Drugs Today, vol. 42, pp. 399–404.
33. Psathas P.A., Kuzmission A., Ikeda K., Yasuo S. (2007) Stability of doripenem for injection (500 mg) in representative infusion fluids and containers. Program and Abstracts of 2007 American Society of Healthsystem Pharmacists summer Meeting; June 24–27, San Francisco, C.A.
34. (2007) Invans [package insert]. Whitehouse Station, NJ: Merk&Co.
35. Kays M.B., Fleming M.R., Cheatham S.C. (2014) Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Ann Pharmacother., vol. 48(2), pp. 178–186.
36. Roberts J.A., Lipman J. (2013) Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med., vol. 41(2), pp. 489–495.
37. Chung E.K., Fleming M.R., Cheatham S.C. (2017) Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients. Ann Pharmacother., vol. 51(3), pp. 209–218.
38. Alobaid A.S., Hites M., Lipman J. (2016) Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. Int. J. Antimicrob Agents., vol. 47(4), pp. 259–268.
